LAAO offers similar overall efficacy and safety to modern antithrombotics, representing a clinical trade-off of accepting upfront procedural risk for robust long-term reduction in non-procedural bleeding, potentially at the cost of a slight numerical increase in ischemic stroke.
There was no significant difference in cardiovascular mortality between LAAO and antithrombotics.
There was no significant difference in all-cause stroke rates between LAAO and antithrombotics.
There was no significant difference in systemic embolism between LAAO and antithrombotics.
There was no significant difference in major bleeding between LAAO and antithrombotics.
Non-procedural bleeding was significantly lower with LAAO compared to antithrombotics.
There was a numerical trend toward more ischemic stroke events with LAAO compared to antithrombotics, though it did not reach statistical significance.
Individual landmark RCTs comparing LAAO to DOACs were considered underpowered to detect small but clinically meaningful differences.
LAAO was characterized as offering a clinical trade-off compared to modern antithrombotics.
This research examined whether a procedure called left atrial appendage occlusion (LAAO) — a small implantable device that blocks a pouch in the heart where blood clots often form in people with atrial fibrillation — works as well and as safely as blood-thinning medications (specifically newer drugs called direct oral anticoagulants, or DOACs). Because the individual clinical trials testing this were each too small to detect subtle differences, the researchers combined data from four major trials, covering nearly 6,000 patients, to get a clearer picture. The study found that LAAO and blood thinners performed similarly on the most serious outcomes: rates of cardiovascular death, stroke overall, systemic embolism, and major bleeding were not statistically different between the two approaches. However, LAAO significantly reduced 'non-procedural' bleeding — bleeding that occurs during day-to-day life rather than from the implant procedure itself — by about 45% compared to blood thinners. On the other hand, there was a trend suggesting LAAO patients may have slightly more ischemic strokes (strokes caused by blockages rather than bleeding), though this difference was not statistically conclusive. This research suggests that choosing between LAAO and blood thinners involves a trade-off: the device carries an upfront risk from the procedure itself, but patients who receive it may experience meaningfully fewer spontaneous bleeding events over time, while potentially facing a slightly higher risk of ischemic stroke. These findings may be useful for patients and their doctors when weighing which approach best fits an individual's specific risk profile, particularly for those who have had serious bleeding problems while on blood thinners.
Knijnik L, Rao B, DeLurgio D. (2026). Pooled Efficacy and Safety of Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulants or Antiplatelets: A Meta-Analysis of the Landmark Randomized Trials.. Journal of cardiovascular electrophysiology. https://doi.org/10.1111/jce.70493